Experienced in Primary Amyloidosis

Dr. Samer K. Khaled

Hematology Oncology | Hematology
Orlando Health Medical Group Inc
1400 S Orange Ave, 
Orlando, FL 
Accepting New Patients
Offers Telehealth
Experienced in Primary Amyloidosis
Orlando Health Medical Group Inc
1400 S Orange Ave, 
Orlando, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Samer Khaled is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Khaled is rated as an Experienced provider by MediFind in the treatment of Primary Amyloidosis. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Khaled is currently accepting new patients.

His clinical research consists of co-authoring 52 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Primary Amyloidosis.

Specialties
Hematology Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Orlando Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 2 Less Insurance Carriers -

Locations

ORLANDO HEALTH MEDICAL GROUP INC
1400 S Orange Ave, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Decitabine, Ipilimumab
Study Phase: Phase 1
A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia
A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2025
Intervention Type: Procedure, Drug
Study Drugs: Decitabine, KRT-232
Study Phase: Phase 1
Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission
Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Clofarabine, Melphalan, Tacrolimus, Sirolimus
Study Phase: Phase 2
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Biological, Other
Study Drugs: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Study Phase: Phase 1
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: October 12, 2021
Intervention Type: Drug
Study Drug: AMV564 Bispecific CD33/CD3 T Cell Engager
Study Phase: Phase 1
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: June 16, 2021
Intervention Type: Drug
Study Drugs: Rigosertib, Azacitidine
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

52 Total Publications

Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
Journal: Leukemia
Published: May 05, 2025
Similar Doctors
Experienced in Primary Amyloidosis
Dr. Tarek M. Mekhail
Hematology Oncology | Hematology | Oncology
Experienced in Primary Amyloidosis
Dr. Tarek M. Mekhail
Hematology Oncology | Hematology | Oncology

Florida Hospital Medical Group Inc

2501 N Orange Ave, Suite 689, 
Orlando, FL 
 (3.4 miles away)
407-303-2024
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tarek Mekhail is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Mekhail is rated as an Elite provider by MediFind in the treatment of Primary Amyloidosis. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Mekhail is currently accepting new patients.

Experienced in Primary Amyloidosis
Dr. Philip A. Pancari
Hematology | Hematology Oncology | Oncology
Experienced in Primary Amyloidosis
Dr. Philip A. Pancari
Hematology | Hematology Oncology | Oncology

Florida Hospital Medical Group Inc

2415 N Orange Ave, Suite 601, 
Orlando, FL 
 (3.3 miles away)
407-303-2070
Languages Spoken:
English, Hindi, Russian, Spanish, Urdu
See accepted insurances
Accepting New Patients

Philip Pancari is a Hematologist and a Hematologist Oncology provider in Orlando, Florida. Dr. Pancari is rated as an Advanced provider by MediFind in the treatment of Primary Amyloidosis. His top areas of expertise are Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Pancari is currently accepting new patients.

Experienced in Primary Amyloidosis
Dr. Thomas J. Katta
Hematology Oncology | Hematology | Oncology
Experienced in Primary Amyloidosis
Dr. Thomas J. Katta
Hematology Oncology | Hematology | Oncology

Thomas J Katta MD PA

922 Lucerne Ter, 
Orlando, FL 
 (0.4 miles away)
407-426-8660
Languages Spoken:
English, French, German, Hebrew, Hindi, Italian, Spanish, Telugu, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Katta is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Katta is rated as a Distinguished provider by MediFind in the treatment of Primary Amyloidosis. His top areas of expertise are Anemia, RUNX1 Familial Platelet Disorder, Paris-Trousseau Thrombocytopenia, and Febrile Neutropenia. Dr. Katta is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khaled's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile